More significantly, our Annexin V assay results display that the KRAS mutant CRC cells show an 8.0% (p < 0.05) greater increase in apoptosis after 60 h of 10 μM PRMT5 inhibitor treatment when compared to the KRAS WT CRC cells (Figure 5). This evidence concerns the gene KRAS and colorectal carcinoma.